Evidence map›Paper›PMID 39854351›Full record

ArticlePLoS biology2025

Rspo3-mediated metabolic liver zonation regulates systemic glucose metabolism and body mass in mice.

Kenji Uno, Takuya Uchino, Takashi Suzuki, Yohei Sayama, Naoki Edo, Kiyoko Uno-Eder, Koji Morita, Toshio Ishikawa, Miho Koizumi, Hiroaki Honda and 2 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. [Research advances on hepatocyte zonal changes in metabolic associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. [Biological characteristics of liver zonation and its role in disease and aging].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenji UnoDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9362-9232
Takuya UchinoDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Takashi SuzukiDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Yohei SayamaDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Naoki EdoTeikyo Academic Research Center, Tokyo, Japan.
Kiyoko Uno-EderTeikyo Academic Research Center, Tokyo, Japan.
Koji MoritaDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Toshio IshikawaDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Miho KoizumiField of Human Disease Models, Tokyo Women's Medical University, Tokyo, Japan.
Hiroaki HondaField of Human Disease Models, Tokyo Women's Medical University, Tokyo, Japan.
Hideki KatagiriDepartment of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuhisa TsukamotoDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unique architecture of the liver consists of hepatic lobules, dividing the hepatic features of metabolism into 2 distinct zones, namely the pericentral and periportal zones, the spatial characteristics of which are broadly defined as metabolic zonation. R-spondin3 (Rspo3), a bioactive protein promoting the Wnt signaling pathway, regulates metabolic features especially around hepatic central veins. However, the functional impact of hepatic metabolic zonation, regulated by the Rspo3/Wnt signaling pathway, on whole-body metabolism homeostasis remains poorly understood. In this study, we analyze the local functions of Rspo3 in the liver and the remote actions of hepatic Rspo3 on other organs of the body by using murine models. Rspo3 expression analysis shows that Rspo3 expression patterns are spatiotemporally controlled in the murine liver such that it locates in the pericentral zones and converges after feeding, and the dynamics of these processes are disturbed in obesity. We find that viral-mediated induction of Rspo3 in hepatic tissue of obesity improves insulin resistance and prevents body weight gain by restoring attenuated organ insulin sensitivities, reducing adipose tissue enlargement and reversing overstimulated adaptive thermogenesis. Denervation of the hepatic vagus suppresses these remote effects, derived from hepatic Rspo3 induction, toward adipose tissues and skeletal muscle, suggesting that signals are transduced via the neuronal communication consisting of afferent vagal and efferent sympathetic nerves. Furthermore, the non-neuronal inter-organ communication up-regulating muscle lipid utilization is partially responsible for the ameliorations of both fatty liver development and reduced skeletal muscle quality in obesity. In contrast, hepatic Rspo3 suppression through Cre-LoxP-mediated recombination system exacerbates diabetes due to glucose intolerance and insulin resistance, promotes fatty liver development and decreases skeletal muscle quality, resulting in obesity. Taken together, our study results reveal that modulation of hepatic Rspo3 contributes to maintaining systemic glucose metabolism and body composition via a newly identified inter-organ communication mechanism.

Indexed as

GlucoseLiverThrombospondinsAdipose TissueAnimalsBody WeightInsulin ResistanceMaleMiceMice, Inbred C57BLObesityThermogenesisWnt Signaling PathwayGlucoseR-spondin3 protein, mouseThrombospondins

Identifiers

PMID39854351
PMCPMC11759367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.